Compare XBIT & MATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XBIT | MATH |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 49.9M |
| IPO Year | 2015 | 2016 |
| Metric | XBIT | MATH |
|---|---|---|
| Price | $1.95 | $1.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 82.6K | 30.2K |
| Earning Date | 11-12-2026 | 08-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $30.47 | N/A |
| P/E Ratio | ★ N/A | $3.10 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.80 | $0.73 |
| 52 Week High | $2.73 | $3.19 |
| Indicator | XBIT | MATH |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 51.80 |
| Support Level | $1.83 | $0.93 |
| Resistance Level | $2.42 | $1.04 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 45.45 | 55.85 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Metalpha Technology Holding Ltd mainly operates in the trading of proprietary digital assets and derivative contracts in Hong Kong. The Company's primary business operations center on digital asset services, offered through its subsidiaries. The Company generates income mainly from executing cryptocurrency-related transactions, including providing derivative solutions to over-the-counter (OTC) clients, issuing derivative products to OTC clients, and engaging in proprietary trading activities. The Company provides crypto derivative solutions and liquidity to its clients, facilitated through its principal trading activities, enabling seamless trading of crypto derivative solutions. The Company generates revenue from Hong Kong.